Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease.
about
Coronary microvascular dysfunction in women: an overview of diagnostic strategiesCYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular anginaExcess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease.Effects of sex on coronary microvascular dysfunction and cardiac outcomes.Coronary microvascular dysfunction: an updateInteraction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease.Current Diagnostic and Therapeutic Strategies in Microvascular Angina.Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance.Epicardial adipose tissue thickness is increased in patients with cardiac syndrome XPET tracers and techniques for measuring myocardial blood flow in patients with coronary artery disease.Coronary microvascular dysfunction: mechanisms and functional assessment.Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation.Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.Myocardial blood flow: Putting it into clinical perspective.Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases.Novel biomarkers of coronary microvascular disease.Current perspectives in coronary microvascular dysfunction.Ischemia and No Obstructive Coronary Artery Disease (INOCA): Developing Evidence-Based Therapies and Research Agenda for the Next Decade.Targeting the dominant mechanism of coronary microvascular dysfunction with intracoronary physiology tests.Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina.Inflammation, coronary flow reserve, and microvascular dysfunction: moving beyond cardiac syndrome X.Quantitation of myocardial blood flow and myocardial flow reserve with 99mTc-sestamibi dynamic SPECT/CT to enhance detection of coronary artery disease.Association of Inflammation and Endothelial Dysfunction with Coronary Microvascular Resistance in Patients with Cardiac Syndrome X.Obstructive sleep apnoea: from respiratory events to coronary microvascular dysfunction.Evaluation of adiponectin and lipoprotein(a) levels in cardiac syndrome X.Differential expression of circulating vascular cell adhesion molecule-1 in subjects with coronary artery disease and cardiac syndrome X without known diabetes mellitus.5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1.Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder.Quantitative Assessment of Coronary Microvascular Function: Dynamic Single-Photon Emission Computed Tomography, Positron Emission Tomography, Ultrasound, Computed Tomography, and Magnetic Resonance Imaging.
P2860
Q27024500-DD911D7A-99FE-4CFD-93FA-969F57E53FFDQ33761436-92A6A6AD-72CC-4BBE-824D-0B9F4200CE8AQ33765268-A2AFB973-53A2-4DDE-9B04-27A5BB46A28DQ33825527-930A007A-BFD8-4D95-9337-197B49E9C339Q34658569-57D7C09A-8401-46FD-A757-32D12C6D9DA2Q35071384-69D435D6-17C2-4573-9BEF-DD0EA33C84F9Q35077560-4FD27C72-44A5-49F6-AC7F-0C675AD3DB1EQ36259181-2BD1DA8D-E547-42B1-A85A-82298478A95CQ37516397-360D4C74-04E8-4CF6-A4EA-67705569E9B4Q38167018-41A160FA-6770-4D38-AF9C-5607818A1BEAQ38259726-5980B7F5-F960-4F5B-A11D-EBB7DFF782EBQ38538168-E647855E-142D-41C3-ACE4-E66E0125F0A6Q38663003-18CA3FB4-B8EF-4324-8C92-97770B1A2195Q38681519-BCB9A82E-C69C-41FC-8E99-1E6060F9D889Q38749160-AD7392D6-1444-48F0-8DE6-BFB80CAB7B7BQ38854433-5AE14A0D-6BED-43EF-8D88-BF1BA3D57E98Q39038913-D45900F0-D4BF-4F00-BB32-ED4758BED2F4Q39176512-438218F1-5219-43D6-B741-68F4D1B03642Q39304682-99953985-EE95-4E9A-AAD1-40E92156F6BCQ40567803-B9AE2362-B73F-4B68-86CD-99DB092FF53BQ42400208-DDFFB53F-3D04-40B7-9802-2F98F41AB43DQ43648743-B8550D5D-300E-48D1-A135-005E8C2A1DBBQ47157935-627CDC0E-4865-42B0-A8BA-6559CA71C0FEQ47676551-B5A997F5-B51F-4001-9FB8-74FA8FBD86DFQ47832287-74ECE535-F233-4F60-A2A5-BC0BE6AE7861Q47837383-8D579CF1-5937-405D-A74E-527F8633C11FQ48305554-ACC07207-7D06-4FD8-90C4-6699400C13CEQ50247985-A4F7D304-36CE-4F7C-8E14-EDE1D5A32A28Q52936656-40B59DC9-027D-40A8-8D6D-40B6B0FD2BBF
P2860
Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Inflammation and microvascular ...... s for coronary artery disease.
@en
Inflammation and microvascular ...... s for coronary artery disease.
@nl
type
label
Inflammation and microvascular ...... s for coronary artery disease.
@en
Inflammation and microvascular ...... s for coronary artery disease.
@nl
prefLabel
Inflammation and microvascular ...... s for coronary artery disease.
@en
Inflammation and microvascular ...... s for coronary artery disease.
@nl
P2093
P1476
Inflammation and microvascular ...... s for coronary artery disease.
@en
P2093
Alejandro Recio-Mayoral
Juan Carlos Kaski
Ornella E Rimoldi
Paolo G Camici
P304
P356
10.1016/J.JCMG.2012.12.011
P577
2013-05-01T00:00:00Z